How Have the Numbers Shaped Up for Lyra Therapeutics (NASDAQ:LYRA)

Earnings results for Lyra Therapeutics (NASDAQ:LYRA)

Lyra Therapeutics, Inc. is estimated to report earnings on 02/16/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.64.

Lyra Therapeutics last announced its earnings results on November 10th, 2020. The reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.08. Lyra Therapeutics has generated $0.00 earnings per share over the last year. Lyra Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, February 16th, 2021 based off prior year’s report dates.

Analyst Opinion on Lyra Therapeutics (NASDAQ:LYRA)

4 Wall Street analysts have issued ratings and price targets for Lyra Therapeutics in the last 12 months. Their average twelve-month price target is $26.00, predicting that the stock has a possible upside of 87.59%. The high price target for LYRA is $28.00 and the low price target for LYRA is $24.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Lyra Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $26.00, Lyra Therapeutics has a forecasted upside of 87.6% from its current price of $13.86. Lyra Therapeutics has received no research coverage in the past 90 days.

Dividend Strength: Lyra Therapeutics (NASDAQ:LYRA)

Lyra Therapeutics does not currently pay a dividend. Lyra Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Lyra Therapeutics (NASDAQ:LYRA)

In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock. 59.26% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Lyra Therapeutics (NASDAQ:LYRA

Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($2.04) to ($2.02) per share.

More latest stories: here